
FDA Approves Koselugo for Adults with Neurofibromatosis Type 1
The U.S. Food and Drug Administration (FDA) has approved Koselugo (selumetinib), an oral MEK inhibitor developed by Alexion, AstraZeneca Rare Disease, for adults with neurofibromatosis

The U.S. Food and Drug Administration (FDA) has approved Koselugo (selumetinib), an oral MEK inhibitor developed by Alexion, AstraZeneca Rare Disease, for adults with neurofibromatosis

Hundreds more patients in England with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will gain earlier access to glofitamab (Columvi) after new guidance from

Vera Therapeutics has taken a major step toward transforming treatment for immunoglobulin A nephropathy (IgAN), submitting a Biologics License Application to the U.S. Food and

My journey started abruptly last year. It was a completely normal day—until it wasn’t. I’m an RN, and I slept most of the day before

I’m Jenna, a 36-year-old married mother of one son, and I have neuroendocrine cancer (NETs). It is a rare type of cancer, and 60% of

Arrowhead Pharmaceuticals has secured its first U.S. approval with Redemplo, an RNA interference therapy cleared by the FDA for adults with familial chylomicronemia syndrome (FCS).

See additional Important Safety Information below. Please read the accompanying full Prescribing Information, including Boxed WARNING, also available at NUPLAZID.com. You are encouraged to report

As reported by PharmaBiz, the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion supporting Orphan Drug Designation (ODD) for
We're proud to share Beverly's healthcare journey, and how she turned living with dystonia into a source of inspiration for others. Read here:
patientworthy.com/2025/12/26/turning-painful-scars-into-guiding-stars-beverlys-journey-with-dysto...
... See MoreSee Less

For many, SSRIs are a daily necessity to be healthy. However, a recent FDA panel has sparked debate over the use of SSRIs by pregnant people, many of whom feel that they need to continue their SSRIs to be the best parents they can be. Read more here:
patientworthy.com/2025/12/26/fda-panel-sparks-debate-over-antidepressant-use-in-pregnancy/
... See MoreSee Less

Eccogene Launches MOSAIC Trial to Test Dual Mechanisms Against Metabolic Liver Disease bit.ly/45c2Id0 Read now at PatientWorthy.com
#PatientWorthy #Mash #metabolicdysfunction-associatedSteatohepatitis #clinicaltrial #mosaictrial
... See MoreSee Less

© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
What best describes you when it comes to rare disease? (check all that apply)
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.